RepliCel Life Sciences Inc
0913693 B.C. Ltd., a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include … Read more
Market Cap & Net Worth: RepliCel Life Sciences Inc (REPCF)
RepliCel Life Sciences Inc (PINK:REPCF) has a market capitalization of $147.16K ($147.16K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #45447 globally and #14292 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying RepliCel Life Sciences Inc's stock price $0.00 by its total outstanding shares 73577807 (73.58 Million).
RepliCel Life Sciences Inc Market Cap History: 2015 to 2025
RepliCel Life Sciences Inc's market capitalization history from 2015 to 2025. Data shows change from $142.01 Million to $147.16K (-53.34% CAGR).
RepliCel Life Sciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how RepliCel Life Sciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.44x
RepliCel Life Sciences Inc's market cap is 0.44 times its annual revenue
2016.65x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $19.48 Million | $167.66K | -$2.78 Million | 116.21x | N/A |
| 2019 | $16.17 Million | $353.74K | -$3.05 Million | 45.70x | N/A |
| 2020 | $12.52 Million | $353.74K | -$1.58 Million | 35.38x | N/A |
| 2021 | $13.34 Million | $353.74K | -$4.07 Million | 37.71x | N/A |
| 2022 | $3.78 Million | $353.74K | -$743.00K | 10.69x | N/A |
| 2023 | $3.31 Million | $353.74K | -$312.00K | 9.36x | N/A |
| 2024 | $154.51K | $353.74K | -$97.29K | 0.44x | N/A |
Competitor Companies of REPCF by Market Capitalization
Companies near RepliCel Life Sciences Inc in the global market cap rankings as of March 19, 2026.
Key companies related to RepliCel Life Sciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
RepliCel Life Sciences Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, RepliCel Life Sciences Inc's market cap moved from $142.01 Million to $ 147.16K, with a yearly change of -53.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $147.16K | -4.76% |
| 2024 | $154.51K | -95.33% |
| 2023 | $3.31 Million | -12.45% |
| 2022 | $3.78 Million | -71.65% |
| 2021 | $13.34 Million | +6.58% |
| 2020 | $12.52 Million | -22.58% |
| 2019 | $16.17 Million | -17.03% |
| 2018 | $19.48 Million | -14.58% |
| 2017 | $22.81 Million | -56.34% |
| 2016 | $52.24 Million | -63.21% |
| 2015 | $142.01 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of RepliCel Life Sciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $147.16K USD |
| MoneyControl | $147.16K USD |
| MarketWatch | $147.16K USD |
| marketcap.company | $147.16K USD |
| Reuters | $147.16K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.